Company profile for Fortress Biotech

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Fortress Biotech ("Fortress" or "the Company") is an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential clinical-stage assets. The company has over 25 programs in clinical development at Fortress, at its majority-owned and majority-controlled subsidiaries and at entities it founded and in which it holds significant minority ownership positions. Such product candidates span ...
Fortress Biotech ("Fortress" or "the Company") is an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential clinical-stage assets. The company has over 25 programs in clinical development at Fortress, at its majority-owned and majority-controlled subsidiaries and at entities it founded and in which it holds significant minority ownership positions. Such product candidates span six large-market therapeutic areas, including oncology, rare diseases and gene therapy, which allow it to create value while mitigating risk for shareholders.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
2 Gansevoort Street, 9th Floor New York, NY 10014
Telephone
Telephone
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/14/3188314/28889/en/Fortress-Biotech-Reports-Third-Quarter-2025-Financial-Results-and-Recent-Corporate-Highlights.html

GLOBENEWSWIRE
14 Nov 2025

https://www.globenewswire.com/news-release/2025/10/21/3170212/28889/en/Fortress-Biotech-and-Subsidiary-Urica-Therapeutics-Announce-First-Patients-Dosed-in-Crystalys-Therapeutics-Global-Phase-3-Trials-of-Dotinurad-for-the-Treatment-of-Gout.html

GLOBENEWSWIRE
21 Oct 2025

https://www.globenewswire.com/news-release/2025/10/01/3159486/28889/en/Fortress-Biotech-and-Cyprium-Therapeutics-Announce-an-Update-on-the-NDA-for-CUTX-101.html

GLOBENEWSWIRE
01 Oct 2025

https://www.globenewswire.com/news-release/2025/10/01/3159491/28889/en/Fortress-Biotech-and-Subsidiary-Urica-Therapeutics-Announce-Crystalys-Therapeutics-205-Million-Series-A-Financing.html

GLOBENEWSWIRE
01 Oct 2025

https://www.globenewswire.com/news-release/2025/09/02/3142697/28889/en/Fortress-Biotech-to-Present-at-the-H-C-Wainwright-27th-Annual-Global-Investment-Conference.html

GLOBENEWSWIRE
02 Sep 2025

https://www.globenewswire.com/news-release/2025/08/14/3133836/28889/en/Fortress-Biotech-Reports-Second-Quarter-2025-Financial-Results-and-Recent-Corporate-Highlights.html

GLOBENEWSWIRE
14 Aug 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty